Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial

被引：0
|
作者：
Vaduganathan, M. [1 ]
Sattar, N. [2 ]
Fitchett, D. [3 ]
Ofstad, A. [4 ]
Brueckmann, M. [5 ,6 ]
George, J. T. [5 ]
Verma, S. [3 ]
Mattheus, M. [7 ]
Wanner, C. [8 ]
Inzucchi, S. E. [9 ]
Zinman, B. [10 ]
Butler, J. [11 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Univ Glasgow, Glasgow, Lanark, Scotland
[3] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada
[4] Boehringer Ingelheim KS, Asker, Norway
[5] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[6] Heidelberg Univ, Mannheim, Germany
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[8] Univ Hosp Wurzburg, Wurzburg, Germany
[9] Yale Univ, Sch Med, Yale New Haven Hosp, New Haven, CT USA
[10] Univ Toronto, Mt Sinai Hosp, Toronto, ON, Canada
[11] Univ Mississippi, Jackson, MS 39216 USA
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
572
引用
收藏
页码：S275 / S275
页数：1
相关论文
共 50 条
  • [31] Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial
    Cooper, Mark E.
    Inzucchi, Silvio E.
    Zinman, Bernard
    Hantel, Stefan
    von Eynatten, Maximilian
    Wanner, Christoph
    Koitka-Weber, Audrey
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 74 (05) : 713 - 715
  • [32] Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
    Sharma, Abhinav
    Inzucchi, Silvio E.
    Testani, Jeffery
    Ofstad, Anne Pernille
    Fitchett, David
    Mattheus, Michaela
    Verma, Subodh
    Zannad, Faiez
    Wanner, Christoph
    Kraus, Bettina
    INTERNIST, 2022, 63 (SUPPL 3): : 316 - 316
  • [33] Empagliflozin's Cardiovascular Impact in High-Risk Patients With Type 2 Diabetes and Obstructive Pulmonary Disease: An Inquiry From EMPA-REG OUTCOME
    Anker, Stefan D.
    Fitchett, David H.
    Zinman, Bernard
    Ofstad, Anne Pernille
    Wanner, Christoph
    Vedin, Ola
    Schinzel, Birgit
    Yaggi, Henry K.
    George, Jyothis T.
    Sander, Leif Erik
    Inzucchi, Silvio E.
    Verma, Subodh
    CIRCULATION, 2020, 142
  • [34] A phase III trial of empagliflozin in patients with Type 2 diabetes with stage 2 or 3 chronic kidney disease (EMPA-REG RENAL™)
    Barnett, A. H.
    Mithal, A.
    Manassie, J.
    Jones, R.
    Rattunde, H.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2014, 31 : 63 - 63
  • [35] Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial
    Odutayo, Ayodele
    Zinman, Bernard
    Wanner, Christoph
    Zwiener, Isabella
    Lund, Soren S.
    Hantel, Stefan
    Fitchett, David
    Udell, Jacob A.
    CJC OPEN, 2024, 6 (07) : 868 - 875
  • [36] Empagliflozin in Resistant Hypertension: Findings From the Empa-reg Outcome Trial
    Ferreira, Joao Pedro
    Fitchett, David
    Ofstad, Anne Pernille
    Kraus, Bettina J.
    Wanner, Christoph
    Zwiener, Isabella
    Lauer, Sabine
    George, Jyothis T.
    Rossignol, Patrick
    Zannad, Faiez
    CIRCULATION, 2019, 140
  • [37] Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
    Sharma, A.
    Inzucchi, S. E.
    Testani, J.
    Ofstad, A. P.
    Fitchett, D.
    Mattheus, M.
    Verma, S.
    Zannad, F.
    Wanner, C.
    Kraus, B. J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 175 - 175
  • [38] Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
    Inzucchi, Silvio E.
    Khunti, Kamlesh
    Fitchett, David H.
    Wanner, Christoph
    Mattheus, Michaela
    George, Jyothis T.
    Ofstad, Anne Pernille
    Zinman, Bernard
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (09): : 3025 - 3035
  • [39] Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD): post hoc analyses of the EMPA-REG OUTCOME trial
    Ferreira, J. P.
    Verma, S.
    David, F.
    Ofstad, A. P.
    Lauer, S.
    Zwiener, I.
    George, J. T.
    Wanner, C.
    Zinman, B.
    Inzucchi, S. E.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S450 - S451
  • [40] Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial
    Inzucchi, Silvio E.
    Wanner, Christoph
    Hehnke, Uwe
    Zwiener, Isabella
    Kaspers, Stefan
    Clark, Douglas
    George, Jyothis T.
    Zinman, Bernard
    DIABETES CARE, 2019, 42 (04) : E53 - E55
12345